National Research Corporation (NRC) P/E Ratio History
Premium ValuationTrading at 37.6x vs 5Y avg 28.3x · 90th percentile · Premium to historical baseline · Data 2013–2026
Loading P/E history...
P/E Ratio Analysis
As of May 30, 2026, National Research Corporation (NRC) trades at a price-to-earnings ratio of 37.6x, with a stock price of $19.53 and trailing twelve-month earnings per share of $0.41.
The current P/E is 33% above its 5-year average of 28.3x. Over the past five years, NRC's P/E has ranged from a low of 12.4x to a high of 42.7x, placing the current valuation at the 90th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.7x, NRC trades at a 65% premium to its sector peers. The sector includes 236 companies with P/E ratios ranging from 0.0x to 188.5x.
Relative to the broader market, NRC commands a significant premium over the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NRC DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NRC Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
NRC P/E vs Peers
Healthcare Data, Analytics and AI peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $14B | 1939.8 | - | -95% | |
| $7B | 20.5Lowest | 1.81 | +3% | |
| $719M | 155.1 | - | +114% | |
| $2B | 128.5 | - | -79% | |
| $7B | 35.8 | 0.43Best | +126%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
NRC Historical P/E Data (2013–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $16.98 | $0.40 | 42.7x | +21% |
| FY2025 Q4 | Dec 31 2025 | $18.77 | $0.51 | 37.0x | +5% |
| FY2025 Q3 | - | $12.78 | $0.71 | 18.1x | -49% |
| FY2025 Q2 | Jun 30 2025 | $16.80 | $0.77 | 22.0x | -38% |
| FY2025 Q1 | Mar 31 2025 | $12.80 | $1.03 | 12.4x | -65% |
| FY2024 Q4 | - | $17.64 | $1.05 | 16.8x | -52% |
| FY2024 Q3 | Sep 30 2024 | $22.86 | $1.13 | 20.2x | -43% |
| FY2024 Q2 | Jun 30 2024 | $22.95 | $1.21 | 19.0x | -46% |
| FY2024 Q1 | Mar 31 2024 | $39.61 | $1.24 | 31.9x | -10% |
| FY2023 Q4 | Dec 31 2023 | $39.56 | $1.25 | 31.6x | -10% |
| FY2023 Q3 | Sep 30 2023 | $44.37 | $1.16 | 38.3x | +8% |
| FY2023 Q2 | Jun 30 2023 | $43.51 | $1.17 | 37.2x | +5% |
| FY2023 Q1 | Mar 31 2023 | $43.51 | $1.21 | 36.0x | +2% |
| FY2022 Q4 | Dec 31 2022 | $37.30 | $1.27 | 29.4x | -17% |
| FY2022 Q3 | Sep 30 2022 | $39.80 | $1.38 | 28.8x | -18% |
| FY2022 Q2 | - | $38.28 | $1.43 | 26.8x | -24% |
| FY2022 Q1 | - | $39.65 | $1.45 | 27.3x | -23% |
| FY2021 Q4 | Dec 31 2021 | $41.52 | $1.47 | 28.2x | -20% |
| FY2021 Q3 | - | $42.17 | $1.41 | 29.9x | -15% |
| FY2021 Q2 | Jun 30 2021 | $45.90 | $1.40 | 32.8x | -7% |
| FY2021 Q1 | Mar 31 2021 | $46.83 | $1.35 | 34.7x | -2% |
| FY2020 Q4 | - | $42.75 | $1.45 | 29.5x | -17% |
| FY2020 Q3 | Sep 30 2020 | $49.21 | $1.47 | 33.5x | -5% |
| FY2020 Q2 | - | $58.21 | $1.41 | 41.3x | +17% |
| FY2020 Q1 | - | $45.48 | $1.40 | 32.5x | -8% |
| FY2019 Q4 | - | $65.94 | $1.26 | 52.3x | +48% |
| FY2019 Q3 | Sep 30 2019 | $57.75 | $1.22 | 47.3x | +34% |
| FY2019 Q2 | Jun 30 2019 | $57.59 | $1.18 | 48.8x | +38% |
| FY2019 Q1 | Mar 31 2019 | $38.60 | $1.17 | 33.0x | -7% |
| FY2018 Q4 | Dec 31 2018 | $38.14 | $1.02 | 37.4x | +6% |
| FY2018 Q3 | Sep 30 2018 | $38.60 | $0.87 | 44.4x | +26% |
| FY2018 Q2 | Jun 30 2018 | $37.40 | $0.69 | 54.2x | +53% |
| FY2018 Q1 | Mar 31 2018 | $29.25 | $0.54 | 54.2x | +53% |
| FY2017 Q4 | Dec 31 2017 | $37.30 | $0.52 | 71.7x | +103% |
| FY2017 Q3 | Sep 30 2017 | $37.70 | $0.50 | 75.4x | +113% |
| FY2017 Q2 | Jun 30 2017 | $26.90 | $0.52 | 51.7x | +46% |
| FY2017 Q1 | Mar 31 2017 | $19.70 | $0.50 | 39.4x | +12% |
| FY2016 Q4 | Dec 31 2016 | $19.00 | $0.48 | 39.6x | +12% |
| FY2016 Q3 | Sep 30 2016 | $16.29 | $0.49 | 33.2x | -6% |
| FY2016 Q2 | - | $13.70 | $0.48 | 28.5x | -19% |
| FY2016 Q1 | - | $15.55 | $0.47 | 33.1x | -6% |
| FY2015 Q4 | - | $16.04 | $0.42 | 38.2x | +8% |
| FY2015 Q3 | Sep 30 2015 | $11.94 | $0.38 | 31.4x | -11% |
| FY2015 Q2 | - | $14.21 | $0.39 | 36.4x | +3% |
| FY2015 Q1 | - | $14.40 | $0.39 | 36.9x | +5% |
| FY2014 Q4 | Dec 31 2014 | $13.99 | $0.44 | 31.8x | -10% |
| FY2014 Q3 | - | $13.01 | $0.43 | 30.3x | -14% |
| FY2014 Q2 | Jun 30 2014 | $13.99 | $0.41 | 34.1x | -3% |
| FY2014 Q1 | Mar 31 2014 | $16.59 | $0.39 | 42.5x | +20% |
| FY2013 Q4 | - | $18.82 | $0.48 | 39.2x | +11% |
| FY2013 Q3 | Sep 30 2013 | $18.83 | $0.92 | 20.5x | -42% |
| FY2013 Q2 | Jun 30 2013 | $18.00 | $1.34 | 13.4x | -62% |
Average P/E for displayed period: 35.3x
What if you invested $1,000 in NRC back in 2013?
Total return with dividends reinvested · 13+ years of data
Calculate ReturnsHow much would $100/month in NRC be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs NRC Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationNRC vs DBVT — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs DBV Technologies S.A..
Compare NowNRC — Frequently Asked Questions
Quick answers to the most common questions about buying NRC stock.
What is NRC's P/E ratio?
National Research Corporation (NRC) trailing twelve-month P/E ratio is 37.6x, based on TTM diluted EPS of $0.41. The 5-year average P/E is 28.3x and the historical range spans 12.4x to 42.7x.
Is NRC stock overvalued or undervalued?
NRC trades at 37.6x P/E, above its 5-year average of 28.3x. The 90th percentile ranking within the 12.4x–42.7x historical range indicates a premium to historical valuation.
Is NRC stock expensive?
Yes, NRC is expensive relative to its own history. The current P/E of 37.6x is above the 5-year average of 28.3x and also above the Healthcare sector median of 22.7x. The stock sits at the 90th percentile of its 5-year valuation range.
What is NRC's historical P/E range?
Over the past 5 years, NRC's P/E ratio has ranged from 12.4x to 42.7x, with a median of 29.4x and an average of 28.3x. The current P/E of 37.6x places the stock at the 90th percentile of this range. Full historical data spans 2013–2026.
How does NRC's P/E compare to the S&P 500?
NRC trades at 37.6x P/E versus the S&P 500 median of 25.2x. The 49% premium to the market typically reflects higher expected earnings growth or quality.
How does NRC's valuation compare to Healthcare peers?
National Research Corporation P/E of 37.6x compares to the Healthcare sector median of 22.7x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is NRC's PEG ratio?
NRC PEG ratio is N/A, based on a P/E of 37.6x and EPS growth of -50.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is NRC's earnings yield?
NRC earnings yield is 2.66%, the inverse of its 37.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.